Arash Ash Alizadeh, M.D., Ph.D.


Stanford University School of Medicine
Prospective Validation and Genetic Basis of a Novel Molecular Risk Predictor for Diffuse large B-Cell Lymphoma

Drug-development is time consuming and costly, consuming on average 10-years and $800-million for each drug to reach patients. We can circumvent these barriers by designing risk-adapted clinical trials testing new therapies. We developed a method for predicting outcomes for the commonest lymphoma, aiming to validate and understand its genetic basis. To learn more, please visit our lab online.